experts25Aug 20, 20221 min readCSL's $11.7B Vifor buy, 2021's biggest biopharma M&A deal, hits antitrust delayLarger mergers and acquisitions often mean more regulations. See how a recent M&A has hit a few months delay due to antitrust laws. It's a great case study to prepare for your future M&As that may occur. https://www.fiercepharma.com/pharma/csls-117b-vifor-buy-largest-biopharma-ma-deal-2021-hits-antitrust-delay #mergersandacquisitions #MandA
Larger mergers and acquisitions often mean more regulations. See how a recent M&A has hit a few months delay due to antitrust laws. It's a great case study to prepare for your future M&As that may occur. https://www.fiercepharma.com/pharma/csls-117b-vifor-buy-largest-biopharma-ma-deal-2021-hits-antitrust-delay #mergersandacquisitions #MandA
コメント